MO · Q4 2025 Earnings
CautiousAltria
Reported January 29, 2026
30-second summary
Altria closed FY2025 with non-GAAP EPS of $5.42 — near the high end of the $5.37–$5.45 floor it set last quarter — on Q4 revenue of $5.85B (-2.1% YoY) and Q4 non-GAAP EPS of $1.30. The actual news is the FY2026 setup: EPS growth guided to 2.5–5.5% (a step down from FY2025's 4.4% actual), CapEx stepping up to $300–$375M (+67% to +71% YoY, ~+69% at midpoint) to fund import-export manufacturing build-out, and a $1.3B non-cash impairment on eVapor intangibles with explicit retreat language — "we intend to maintain a measured approach to our investments in eVAPOR until the regulatory framework is functioning as intended." Q4 Marlboro retail share fell to 39.8% (FY2025 share held at 40.5%), confirming the trade-down dynamic flagged last quarter is intensifying.
Headline numbers
EPS
Q4 FY2025
$1.30
Revenue
Q4 FY2025
$5.85B
-2.1% YoY
Gross margin
Q4 FY2025
62.1%
Operating margin
Q4 FY2025
28.2%
Key financials
Q4 FY2025| Metric | Q4 FY2025 | YoY | Q3 FY2025 | QoQ |
|---|---|---|---|---|
| Revenue | $5.85B | -2.1% | $6.07B | -3.7% |
| EPS | $1.30 | — | $1.45 | -10.3% |
| Gross margin | 62.1% | — | 62.8% | -70bps |
| Operating margin | 28.2% | — | 53.2% | -2500bps |
Guidance
FY2025 EPS met guidance; FY2026 guidance shows modest 2.5–5.5% EPS growth with elevated CapEx investment of $300–$375M to support manufacturing expansion.
Guidance is issued for both next quarter and the full year. Both may appear below.
Actuals vs prior guidance
| Metric | Period | Prior guide | Actual | Δ | Result |
|---|---|---|---|---|---|
| Adjusted diluted EPS | FY2025 | $5.37 to $5.45 | $5.42 | in-line (at midpoint of $5.41 guide) | Beat |
New guidance
| Metric | Period | Guide | YoY |
|---|---|---|---|
| Adjusted diluted EPS | FY2026 | $5.56 to $5.72 | 2.5% to 5.5% |
| Adjusted effective tax rate | FY2026 | 22.5% to 23.5% | — |
| Capital expenditures | FY2026 | $300 million to $375 million | — |
| Depreciation and amortization expenses | FY2026 | approximately $225 million | — |
Segment performance
Q4 FY2025| Segment | Q4 FY2025 | YoY |
|---|---|---|
| Smokeable Products | $5.119B | -2.7% |
| Oral Tobacco Products | $0.706B | +2.0% |
| E-Vapor Products | $0.021B | -4.5% |
Platform metrics
Q4 FY2025| Segment | Q4 FY2025 |
|---|---|
| Marlboro Retail Share | 39.8% |
| on! Nicotine Pouch Share (U.S. Oral Category) | 7.7% |
| Domestic Cigarette Shipment Volume (YoY) | -7.9% |
| Oral Tobacco Shipment Volume (YoY) | -6.3% |
| Revenues net of Excise Taxes | $5.079B |
Profitability
Q4 FY2025| Segment | Q4 FY2025 |
|---|---|
| Adjusted OCI Margin (Smokeable Products) | 60.4% |
| Adjusted OCI Margin (Oral Tobacco Products) | 64.5% |
Other KPIs
Q4 FY2025| Segment | Q4 FY2025 |
|---|---|
| Share Repurchases (Q4) | $288M |
Management tone
Q2 FY2025 narrowed-not-raised on conditional language → Q3 FY2025 raised the low end but pre-warned Q4 + pushed ACE to 2027 → Q4 FY2025 took a $1.3B eVapor impairment and explicitly retreated.
The eVapor strategic posture flipped from "growth lever" to "wait and see." Three quarters ago management framed NJOY as central to the smoke-free transition; two quarters ago NJOY re-entry timing was tied to "market conditions"; last quarter the ACE timeline was pushed to early 2027 on the JUUL ITC ruling. This quarter the retreat is total: "we intend to maintain a measured approach to our investments in eVAPOR until the regulatory framework is functioning as intended and enforcement actions meaningfully address the illicit market." That language, combined with the $1.3B intangible impairment, is management writing down the NJOY thesis. The capital allocation pivot is to nicotine pouches.
The illicit-enforcement timeline got explicitly extended. Q2 FY2025 management called illicit-vape stabilization "too soon to call a trend." Q3 FY2025 retained cautious optimism. This quarter Sal stated outright: "we now believe that effective, sustained enforcement will develop over time at a more gradual pace." This is the justification for the impairment — management is admitting its prior timeline was wrong. The downstream implication is that the cross-category cigarette decline attribution was also revised down, from 3–4% to 2–3% — meaning the secular cigarette volume bleed is structurally a little worse than previously framed.
The pouch story moved from share-gainer to share-loser with a new product hope. Q2 FY2025 framed on! as gaining share; Q3 FY2025 showed pouch-category share down 410bps YoY despite holding total-category share; this quarter on!'s pouch-category share fell another 530bps YoY to 13.4% and total oral category share dropped 100bps YoY to 7.7%. Management has effectively rebased the smoke-free thesis on on! PLUS: "We believe [on! PLUS] is a premium, differentiated product that is well positioned to meaningfully participate in this growth." on! PLUS is the new hope; on! Classic appears to be in defensive mode against deep-discount pouch competitors.
Hedging language thickened materially. Last quarter's tone was cautious. This quarter Billy used "we're hopeful that 2026 will bring consistent enforcement" — a notable downgrade from prior quarters where management was willing to make directional commitments. Combined with refusal to size on! PLUS early performance in Q&A (Faham/UBS), the call had the texture of a management team buying optionality on a longer transition timeline.
Capital allocation pivot is now explicit. Q3 FY2025 doubled buyback authorization to $2.0B as the cleanest bull signal. Q4 FY2025 spent $288M on buybacks — a steady pace — but the bigger capital allocation signal is the +67–71% CapEx step-up for import-export infrastructure. Management told Stifel's Matt Smith the CapEx is "relatively low for a company of their size" and signaled it could persist beyond 2026 ("disciplined, diligent capital deployment without providing guidance on future CapEx"). The buyback is no longer the only capital story.
Recurring themes management leaned on this quarter:
Risks management surfaced:
Q&A highlights
Matt Smith · Stifel
Matt asked for color on the scope of the import-export program, noting that approximately 3% of PACs currently benefit from FET benefits. He also asked whether 2026 CapEx guidance of $300-$375M represents a one-time increase or multi-year elevation.
Management confirmed the CapEx increase is primarily driven by import-export investments. They emphasized these investments provide duty drawback benefits and long-term manufacturing capabilities for smoke-free products. They characterized the CapEx level as relatively low for a company of their size and indicated disciplined, diligent capital deployment without providing guidance on future CapEx.
Bonnie Herzog · Goldman Sachs
Bonnie questioned whether aggressive BASIC promotional strategy is intended to offset net price realization pressures through import-export ramp, and expressed concern that without significant import-export activity growth, smokable dollar profit growth will remain negative. She also raised concerns about Marlboro retail share dropping below 40% for the first time and potential cannibalization from BASIC.
Management disagreed with linking BASIC strategy to import-export duty drawback benefits, characterizing them as independent decisions. They emphasized BASIC is deployed in ~30,000 stores in economically stressed areas and serves to capture consumers from deep discount brands. On Marlboro, management defended the brand strategy focused on long-term profitability maximization and stated analytics show minimal cannibalization from BASIC. They attributed some Marlboro share pressure to temporary eVapor availability issues due to enforcement.
Eric Serrata · Morgan Stanley
Eric asked about increased smoking incidents among younger legal-aged nicotine users evident in popular press, and requested color on OnPlus pricing strategy positioning relative to OnClassic. He also asked for sizing on double-duty drawback potential beyond the KT&G partnership.
Management referenced their vision of responsibly moving consumers to smoke-free products and called for FDA expedited authorization. On OnPlus pricing, they confirmed it is differentiated and commands a premium, directing analyst to nicotine.com for price comparisons versus OnClassic. They noted various introductory promotional pricing by state at retail launch. On double-duty drawback, they explained the cap is determined by matching exports with imports and indicated continued pursuit of partnership opportunities without detailing specific companies.
Faham Baig · UBS
Faham noted controllable costs were up 14.5% in Q4 versus 9.5% nine-month run rate and asked if import-export investments were the sole driver. He also requested clarification on OnPlus national rollout timeline and early market share data, and asked about supply chain concerns.
Management confirmed import-export manufacturing investments were predominantly responsible for the Q4 cost spike, citing different pack configurations and capabilities required for international markets (e.g., track and trace). They confirmed national OnPlus rollout through H1 2026. Management declined to share exact volumes or market shares, citing the messy launch (three-state initial launch followed by FDA pilot program halt and resumption). They shared positive anecdotal consumer feedback on mouthfeel and flavor differentiation and confirmed no supply chain concerns.
Damian McNeila · Deutsche Bank
Damian asked whether the 30,000-store BASIC deployment represents a ceiling or if stores could be added in 2026. He requested payback time on manufacturing facility investments for import-export and asked whether Q4 cost elevation will repeat in Q1-Q2 or stabilize in H2.
Management indicated the 30,000 stores represent the current scope but will monitor and potentially adjust at the margins based on economic conditions. They characterized BASIC as similar to the historical L&M strategy. Regarding import-export ROI, management stated the payback is less than one year. On costs, they confirmed elevated investments will continue initially as the company enters different markets and partnerships, with back-half improvement expected as volumes ramp.
Answers to last quarter's watch list
What to watch into next quarter
Q1 FY2026 non-GAAP EPS vs prior year. Management explicitly guided H2-weighted growth, which means H1 will look weak. Q1 FY2026 EPS below Q1 FY2025's print would be expected, but a decline of more than ~3% would put the 2.5% low end of FY2026 guide at risk.
Marlboro retail share trajectory from Q4's 39.8% / FY2025's 40.5%. Q4 specifically dipped below 40%. Another step down toward 39% confirms BASIC cannibalization is real and management's "minimal cannibalization" claim to Bonnie Herzog was directional spin. The smokeable OCI margin line is downstream of this.
on! U.S. oral category share from 7.7% and pouch-category share from 13.4%. If on! PLUS national rollout in H1 FY2026 doesn't arrest the decline in either metric, the smoke-free transition thesis is at risk and the $1.3B eVapor impairment has a sequel coming.
Smokeable and Oral Tobacco adj. OCI margins. Q4 compressed 80bps and 500bps YoY respectively. Management says this is upfront cost timing tied to import-export build-out; if Q1 doesn't show partial recovery, the investment economics are running heavier than guided.
Any quantification of on! PLUS early performance. Management refused to share volumes or market share this quarter. A first data point on Q1 FY2026 — even regional share in the three initial launch states — would either validate the on! PLUS thesis or expose it.
Q1 FY2026 buyback pace vs FY2025's $1.0B run-rate. Steady or up = capital allocation discipline intact. Cut materially = signal that CapEx step-up is eating into shareholder return capacity.
Sources
- Altria Q4 FY2025 Earnings Press Release (Exhibit 99.1), SEC filing: https://www.sec.gov/Archives/edgar/data/764180/000076418026000007/exhibit991erq42025.htm
- Altria Q3 FY2025 Earnings Press Release (Exhibit 99.1), SEC filing: https://www.sec.gov/Archives/edgar/data/764180/000076418025000128/exhibit991erq32025.htm
Get the next brief, free.
We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.
This is not investment advice.